CA
BIB icon

Calton & Associates’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Calton & Associates’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,047
Closed -$70K – 435
2017
Q4 		$70K Buy
+1,047
New +$59.1K 0.02% 572

Other funds holding BIB

OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
BA
BKS Advisors Southfield, Michigan $249M AUM 14.37% 1-Year Est. Return
BRC
Bell Rock Capital Rehoboth Beach, Delaware $81M AUM 9.85% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $872M AUM 26.12% 1-Year Est. Return
SBIA
Sheaff Brock Investment Advisors Indianapolis, Indiana $1.09B AUM 14.4% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return

Calton & Associates's BIB Position: Q1 2018 in Review

Calton & Associates sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2018, closing a stake of 1,047 shares — an estimated $70K sold.

Calton & Associates first reported a position in BIB in Q4 2017 and held it in 1 quarter. The position peaked at $70K in Q4 2017. 41 funds tracked by Wall St. Rank hold BIB as of Q1 2018.

  • Calton & Associates reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q1 2018 after selling out during the quarter.
  • Calton & Associates sold 1,047 ProShares Ultra NASDAQ Biotechnology shares in Q1 2018, an estimated $70K.
  • Calton & Associates first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2017 and held it in 1 quarter.
  • Calton & Associates's ProShares Ultra NASDAQ Biotechnology position peaked at $70K in Q4 2017.
  • 41 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.